Restrictive pulmonary deficit is associated with inflammation in sub-optimally controlled obese diabetics

Journal of Thoracic Disease

Volumn 5, Issue 3, 2013, Pages 289-297

  Pinto Pereira, Lexley M ^a   Seemungal, Terence A R ^a   Teelucksingh, Surujpal ^a   Shivananda Nayak, B ^a  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

Author keywords

Diabetes mellitus type 2; Impaired pulmonary function; Obesity; Systemic inflammation

Indexed keywords

BECLOMETASONE DIPROPIONATE; C REACTIVE PROTEIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SALBUTAMOL;

ACANTHOSIS NIGRICANS; ADULT; AGING; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; EDUCATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HIP CIRCUMFERENCE; HUMAN; HYPERTENSION; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PNEUMONIA; RESIDUAL VOLUME; RESTRICTIVE LUNG DISEASE; SMOKING; SOCIAL ASPECT; SPIROMETRY; SYSTOLIC BLOOD PRESSURE; TRINIDAD AND TOBAGO; VASOCONSTRICTION; WAIST CIRCUMFERENCE;

EID: 84881511518     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.07.06     Document Type: Article

References (34)

1. Ford ES, Mannino DM, National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Prospective association between lung function and the incidence of diabetes: findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Diabetes Care 2004;27:2966-70.
2. Walter RE, Beiser A, Givelber RJ, et al. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med 2003;167:911-6.
3. Yeh HC, Punjabi NM, Wang NY, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2008;31:741-6.
4. Lee HM, Chung SJ, Lopez VA, et al. Association of FVC and total mortality in US adults with metabolic syndrome and diabetes. Chest 2009;136:171-6.
5. Lee HM, Le TV, Lopez VA, et al. Association of C-reactive protein with reduced forced vital capacity in a nonsmoking U.S. population with metabolic syndrome and diabetes. Diabetes Care 2008;31:2000-2.
6. Lim SY, Rhee EJ, Sung KC. Metabolic syndrome, insulin resistance and systemic inflammation as risk factors for reduced lung function in Korean nonsmoking males. J Korean Med Sci 2010;25:1480-6.
7. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-5.
8. Thorington P, Avila G, Haynes C, et al. FEV1 is inversely related to frequency of chest infections in chronic disease patients in Trinidad and Tobago. West Indian Med J 2007;43:0-40.
9. Thorington P, Rios M, Avila G, et al. Prevalence of chronic obstructive pulmonary disease among stable chronic disease subjects in primary care in Trinidad, West Indies. J Thorac Dis 2011;3:177-82.
10. Ferguson TS, Tulloch-Reid MK, Wilks RJ. The epidemiology of diabetes mellitus in Jamaica and the Caribbean: a historical review. West Indian Med J 2010;59:259-64.
11. Healthy Caribbean Coalition - Background paper and fact sheet for the Healthy Caribbean -2008-first Caribbean Chronic Disease Conference- No1. Accessed 2011. Available online: www.healthycaribbean.org/hcc/fact_ sheet_1.html
12. Cooper RS, Rotimi CN, Kaufman JS, et al. Prevalence of NIDDM among populations of the African diaspora. Diabetes Care 1997;20:343-8.
13. Gulliford MC, Mahabir D, Rocke B. Diabetes-related inequalities in health status and financial barriers to health care access in a population-based study. Diabet Med 2004;21:45-51.
14. Gläser S, Ittermann T, Koch B, et al. Airflow limitation, lung volumes and systemic inflammation in a general population. Eur Respir J 2012;39:29-37.
15. Rasmussen F, Mikkelsen D, Hancox RJ, et al. High-sensitive C-reactive protein is associated with reduced lung function in young adults. Eur Respir J 2009;33:382-8.
16. Available online: http://www.idf.org/webdata/docs/MetS_def_ update2006.pdf
17. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 2005;26:153-61.
18. Burke JP, Hale DE, Hazuda HP, et al. A quantitative scale of acanthosis nigricans. Diabetes Care 1999;22:1655-9.
19. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87.
20. Brown PH, Teelucksingh S, Matusiewicz SP, et al. Cutaneous vasoconstrictor response to glucocorticoids in asthma. Lancet 1991;337:576-80.
21. Hosseinpoor AR, Parker LA, Tursan d'Espaignet E, et al. Social determinants of smoking in low- and middle-income countries: results from the World Health Survey. PLoS One 2011;6:e20331. 22. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr 2008;32:638-44.
22. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr 2008;32:638-44.
23. Pinto Pereira LM, Seemungal TA, Teelucksingh S, et al. Markers of lung function and inflammation in West Indian diabetics. Eur Respir J 2010;1:18-22.
24. Seemungal T, Pinto Pereira LM, Teelucksingh S, et al. Inflammation in diabetes Is related directly to glycaemic control and inversely to FEV1. Am J Respir Crit Care Med 2011;183:A1326.
25. Teelucksingh S, Jaimungal S, Pinto Pereira L, et al. Does insulin resistance co-exist with glucocorticoid resistance in the metabolic syndrome? Studies comparing skin sensitivity to glucocorticoids in individuals with and without acanthosis nigricans. Cardiovasc Diabetol 2012;11:31.
26. Ruiz JR, Rizzo NS, Ortega FB, et al. Markers of insulin resistance are associated with fatness and fitness in school-aged children: the European Youth Heart Study. Diabetologia 2007;50:1401-8.
27. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80.
28. Dennis RJ, Maldonado D, Rojas MX, et al. Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. BMC Pulm Med 2010;10:38.
29. Wannamethee SG, Shaper AG, Rumley A, et al. Lung function and risk of type 2 diabetes and fatal and nonfatal major coronary heart disease events: possible associations with inflammation. Diabetes Care 2010;33:1990-6.
30. Chance WW, Rhee C, Yilmaz C, et al. Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy. Diabetes Care 2008;31:1596-601.
31. Hsia CC, Raskin P. Lung involvement in diabetes: does it matter?. Diabetes Care 2008;31:828-9.
32. Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and Type 2 diabetes: findings from the British Women's Heart and Health Study. Diabetologia 2004;47:195-203.
33. Litonjua AA, Lazarus R, Sparrow D. Lung function in type 2 diabetes: the Normative Aging Study. Respir Med 2005;99:1583-90.
34. Yeh HC, Punjabi NM, Wang NY, et al. Vital capacity as a predictor of incident type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2005;28:1472-9.